Neuromyelitis Optica Clinical Trial
Official title:
Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)
Verified date | April 2024 |
Source | Tianjin Medical University General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory disease of the central nervous system characterized by relapsing optic neuritis and longitudinal extensive transverse myelitis. The specific autoantibody against aquaporin 4 (AQP4-ab) has been suggested to contribute to the pathogenesis of the disease. Peripheral blood plasma cells are a major source of AQP4-ab. Previous studies have observed increased IL-6 levels in serum and cerebrospinal fluid of patients with NMOSD, particularly during relapses. Exogenous interleukin (IL)-6 promotes the survival of plasma cells and their production of AQP4-ab in vitro. And blockade of IL-6 receptor signaling by an anti-IL-6 receptor antibody reduces the survival of plasma cells in vitro. Tocilizumab (ACTEMRA®), a humanized monoclonal antibody against the IL-6 receptor, has shown beneficial clinical effects in some patients with NMOSD when concomitant immunosuppressive medications were administered. However, the long-lasting biological effects of preceding immunotherapies such as rituximab might overlap with the subsequent tocilizumab therapy. To reduce the side effects of concomitant treatments to large extent and verify the beneficial effects of tocilizumab, we evaluate the safety and efficacy of tocilizumab as monotherapy in patients with NMOSD.
Status | Completed |
Enrollment | 10 |
Est. completion date | May 15, 2018 |
Est. primary completion date | February 15, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of NMOSD, as defined by 2015 criteria. 2. NMOSD patients with at least one attack requiring rescue therapy in the last year or two attacks requiring rescue therapy in the last 2 years. 3. Provision of written informed consent to participate in the study. 4. Peripheral blood B cell count must be normal (5-20% of total lymphocytes) in subjects before administration of tocilizumab. 5. EDSS <= 7.5 (8 in special circumstances). Exclusion Criteria: 1. Current evidence or known history of clinically significant infection (HSV, VZV, CMV, EBV, HIV, Hepatitis viruses, Syphilis, etc) 2. Pregnant, breastfeeding, or child-bearing potential during the course of the study 3. Patients will not participate in any other clinical therapeutic study or will not have participated in any other experimental treatment study within 30 days of screening 4. Participation in another interventional trial within the last 3 months 5. Heart or kidney insufficiency 6. Tumor disease currently or within last 5 years 7. Clinically relevant liver, kidney or bone marrow function disorder 8. Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal. 9. Receipt of IVIG within 1 month prior to randomization. 10. Receipt of any other concomitant immunosuppressive therapies including corticosteroids, azathioprine, mycophenolate mofetil. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Medical University General Hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Fu-Dong Shi |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median Number of Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks Per Year | Compare annual relapses rate before and one year after initial tocilizumab administration | Baseline, 12 months | |
Secondary | Number of Participants with Adverse Events | All adverse events and side effects related to this drug will be recorded. | Baseline, 12 months | |
Secondary | Neurological Disability - Expanded Disability Scale Score (EDSS) | The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death. | Baseline, 12 months | |
Secondary | Timed 25-foot Walk | The Timed 25-Foot Walk test is a quantitative measure of lower extremity function. If required, the subject may use an appropriate assistive device to walk as quickly as he/she can from one end to the other end of a clearly marked, unobstructed, 25-foot course. | Baseline, 12 months | |
Secondary | Change in Visual Acuity in eyes involved in NMOSD | 100% visual acuity and 2.5% contrast visual acuity are examined with high-contrast Sloan letter charts, which are readily available and provide a practical, quantitative, and standardized assessment of visual function. Each chart consists of rows of black letters (decreasing in size from top to bottom) on a white background. | Baseline, 12 months | |
Secondary | Retinal Nerve Fiber Layer (RNFL) Thickness Determination | Compared RNFL by use of Optical Coherence Tomography (OCT) before and one year after initial tocilizumab administration | Baseline, 12 months | |
Secondary | Ganglion Cell Complex (GCC) Thickness Determination | Compared GCC by use of Optical Coherence Tomography (OCT) before and one year after initial tocilizumab administration | Baseline, 12 months | |
Secondary | Full Field Visual Evoked Response (VEP) P100 waves | To determine the latency and amplitude of full field visual evoked response. | Baseline, 12 months | |
Secondary | Number of new lesions by T2 hyperintensity in the spinal cord and brain MRI | MRIs will be performed for standard of care purposes and will be used to evaluate imaging relapses. For this trial, the MRIs will be analyzed for counting the number of new lesions by T2 hyperintensity in the spinal cord and brain. | Baseline, 12 months | |
Secondary | Counts of peripheral blood plasma cells | Compare peripheral blood plasma cells before and one year after initial tocilizumab administration | Baseline, 12 months | |
Secondary | Determination of serum immunoglobulins | Compare immunoglobulins before and one year after initial tocilizumab administration | Baseline, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02283671 -
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
|
Phase 1 | |
Recruiting |
NCT01024985 -
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
|
N/A | |
Recruiting |
NCT04601142 -
Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
|
||
Completed |
NCT03942952 -
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
|
||
Recruiting |
NCT05573711 -
Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
|
||
Not yet recruiting |
NCT06118398 -
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
|
||
Recruiting |
NCT05566769 -
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
|
N/A | |
Withdrawn |
NCT03829566 -
Autologous Transplant To End NMO Spectrum Disorder
|
Phase 2/Phase 3 | |
Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT03350633 -
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
Recruiting |
NCT05356858 -
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
|
Phase 2 | |
Recruiting |
NCT05982925 -
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
|
||
Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
Terminated |
NCT02398994 -
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
|
Phase 3 | |
Withdrawn |
NCT02087813 -
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
|
Phase 1 | |
Terminated |
NCT01339455 -
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
|
Phase 1/Phase 2 | |
Recruiting |
NCT02021825 -
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
|
Phase 4 | |
Active, not recruiting |
NCT04614454 -
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
|
Phase 2 | |
Recruiting |
NCT03370965 -
Optic Neuritis Differential Diagnosis Study
|
N/A | |
Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 |